DSGN vs EDIT

Design Therapeutics, Inc. vs Editas Medicine, Inc. — Valuation Comparison 2026

DSGN

Biotechnology
Design Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$10.74
Last close
Models
7/13
Active
VS

EDIT

Biotechnology
Editas Medicine, Inc.
Quality
6.5
out of 10
Value Trap
18
SAFE
Price
$3.43
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType DSGN Fair ValueDSGN Upside EDIT Fair ValueEDIT Upside
Bayesian DCF Intrinsic $2.99 -72.2% $1.15 -66.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.57 -94.7% $1.32 -61.6%
Dynamic NAV Asset-Based $2.71 -74.8% $1.28 -62.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DSGN vs EDIT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DSGN vs EDIT — Which Stock Is More Undervalued?

EDIT scores higher with a 6.5/10 quality rating vs DSGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Design Therapeutics, Inc. (DSGN) and Editas Medicine, Inc. (EDIT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DSGN currently trades at $10.74 with a QOC of 4.1/10, while EDIT trades at $3.43 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).